Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
Objectives: Despite concerted efforts, Mycobacterium tuberculosis (M.tb), the pathogen that causes tuberculosis (TB), continues to be a burden on global health, regaining its dubious distinction in 2022 as the world's biggest infectious killer with global COVID-19 deaths steadily declining. The...
Main Authors: | Sasha E. Larsen, Susan L. Baldwin, Rhea N. Coler |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-05-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223001145 |
Similar Items
-
Editorial: Beyond Th1: Novel concepts in tuberculosis vaccine immunology
by: Karin Dijkman, et al.
Published: (2022-11-01) -
An RNA-Based Vaccine Platform for Use against <i>Mycobacterium tuberculosis</i>
by: Sasha E. Larsen, et al.
Published: (2023-01-01) -
Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development
by: Zhidong Hu, et al.
Published: (2022-06-01) -
Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment
by: Sasha E. Larsen, et al.
Published: (2018-05-01) -
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
by: Laura Matarazzo, et al.
Published: (2023-04-01)